Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 413 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
bioMérieux invests in France with a new facility to produce innovative diagnostics for the European market
Regulatory Filings Classification · 25% confidence The document is a corporate press release announcing a strategic €250 million investment to build a new manufacturing facility in France. It is neither an earnings release nor an annual/interim report, audit, governance statement, merger filing, dividend notice, nor a presentation. It does not involve share issues, voting results, legal proceedings, or executive appointments. It is a general corporate announcement with no specialized filing type, so it falls into the fallback “Regulatory Filings” category (RNS).
2026-05-29 English
bioMérieux investit en France dans une nouvelle usine de production de diagnostics innovants à destination du marché européen
Regulatory Filings Classification · 70% confidence The document is a corporate press release announcing a strategic €250 million investment to build a new production facility in France. It does not contain financial results, fundraising or financing details, nor is it an earnings release, board change, ESG report, or any regulatory filing of a specific form. It is a general corporate announcement. Under our taxonomy, this best fits the fallback category for miscellaneous regulatory announcements: RNS (Regulatory Filings).
2026-05-29 French
Avril 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Major Shareholding Notification Classification · 100% confidence The document provides monthly information about the total number of voting rights and shares as required by French commercial code article L. 233-8 II and the AMF regulation article 223-16. It includes specific data as of 30/04/2026 and is a formal notification of share and voting rights counts. This matches the definition of a Major Shareholding Notification (MRQ), which involves reporting changes or status of significant share ownership or voting rights. The document is short and focused solely on voting rights and share counts, not a full report or announcement of a meeting or financial results.
2026-05-04 French
bioMérieux – First-Quarter 2026 Business Review
Earnings Release Classification · 92% confidence The document is a press release titled “First-Quarter 2026 Business Review” with summary financial performance, organic sales trends, guidance revision, and key metrics for Q1 2026. It provides headline quarter results, product/regional breakdown tables, commentary by the CEO, and a link to an upcoming investor presentation. This matches the definition of an Earnings Release (ER) – the initial announcement of quarterly financial results with key highlights. It is not a full interim/quarterly report (IR) but a summary release of Q1 results. Therefore, filing code ER is appropriate. Q1 2026
2026-04-23 English
bioMérieux – Information financière du 1er trimestre 2026
Earnings Release Classification · 88% confidence The document is a press release presenting bioMérieux’s first-quarter 2026 financial results: it includes key highlights (organic revenue growth, major product performance), tables of revenue by application and region, management commentary, outlook revision, webcast invitation, and financial calendar. This is the initial announcement of quarterly results rather than a full interim report or an announcement pointing to a separate document. Therefore it is classified as an Earnings Release. Q1 2026
2026-04-23 French
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries
Regulatory Filings Classification · 30% confidence The document is a corporate news release from bioMérieux announcing the publication of a multi‐country health economic analysis on rapid diagnostics in sepsis care. It is not an annual, interim, or earnings report; it does not describe board or capital changes, voting results, or legal proceedings; nor is it a detailed investor presentation or financial supplement. It primarily serves as a press release and does not neatly fit into any specific category. Therefore, it falls into the fallback category of a general regulatory announcement (RNS).
2026-04-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.